Instrument Inactif

Autres langues Teva Pharmaceutical Industries Limited NYSE

Actions

TEVA

US8816242098

Produits pharmaceutiques

Autres langues

09/10	Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says
09/10	Teva Pharmaceutical Industries Ltd. Through Its U.S. Affiliate Teva Pharmaceuticals Announces U.S. Food And Drug Administration Approval Of WELTRUZA For Extended-Release Injectable Suspension For Adults With Schizophrenia
09/10	Teva Pharmaceuticals Shares Rise After FDA Approves Weltruza for Schizophrenia
09/10	Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults
09/10	Teva wins FDA approval for monthly schizophrenia injection Weltruza
05/10	Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette syndrome
05/10	Teva Pharmaceuticals - Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
02/10	Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates
02/10	Samsung Bioepis Signs Partnership Agreement with Teva for Two Biosimilar Candidates
01/10	Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
01/10	Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates
30/09	TAPI (Technology & API Services) Announces Appointment of Serge Rogasik as Chief Executive Officer
29/09	Afternoon Meeting: La renta variable desafía la presión
29/09	Aktien trotzen dem Druck
29/09	Stocks Defy the Pressure
29/09	Morning Meeting: Los bonos elevan la presión
29/09	Morning Meeting: Anleihen erhöhen den Druck
29/09	Bonds Turn Up the Pressure
28/09	Teva Pharmaceuticals Gets FDA Approval for Bone Drug as Biosimilar
28/09	Teva Reports FDA Approval for Degevma
28/09	Teva Pharmaceutical Industries Ltd. Receives U.S. FDA Approval Of DEGEVMA (Denosumab-Adet) As A Biosimilar To Xgeva
28/09	Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says
23/09	Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says
22/09	Teva Pharmaceutical Industries Insider Sold Shares Worth $285,215, According to a Recent SEC Filing
22/09	Teva Pharmaceutical Industries Insider Sold Shares Worth $14,356,802, According to a Recent SEC Filing